These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 28584008)

  • 21. Antibodies against infliximab are associated with de novo development of antibodies to adalimumab and therapeutic failure in infliximab-to-adalimumab switchers with IBD.
    Frederiksen MT; Ainsworth MA; Brynskov J; Thomsen OO; Bendtzen K; Steenholdt C
    Inflamm Bowel Dis; 2014 Oct; 20(10):1714-21. PubMed ID: 25069030
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An Engineered Monovalent Anti-TNF-α Antibody with pH-Sensitive Binding Abrogates Immunogenicity in Mice following a Single Intravenous Dose.
    Watkins JM; Watkins JD
    J Immunol; 2022 Aug; 209(4):829-839. PubMed ID: 35896334
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Optimizing biological treatment in rheumatoid arthritis with the aid of therapeutic drug monitoring.
    Eng GP
    Dan Med J; 2016 Nov; 63(11):. PubMed ID: 27808043
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analytical ultracentrifugation with fluorescence detection system reveals differences in complex formation between recombinant human TNF and different biological TNF antagonists in various environments.
    Krayukhina E; Noda M; Ishii K; Maruno T; Wakabayashi H; Tada M; Suzuki T; Ishii-Watabe A; Kato M; Uchiyama S
    MAbs; 2017; 9(4):664-679. PubMed ID: 28387583
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outpatient Ulcerative Colitis Primary Anti-TNF Responders Receiving Adalimumab or Infliximab Maintenance Therapy Have Similar Rates of Secondary Loss of Response.
    Ma C; Huang V; Fedorak DK; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
    J Clin Gastroenterol; 2015 Sep; 49(8):675-82. PubMed ID: 25389599
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-Tumor Necrosis Factor With a Glyco-Engineered Fc-Region Has Increased Efficacy in Mice With Colitis.
    Bloemendaal FM; Levin AD; Wildenberg ME; Koelink PJ; McRae BL; Salfeld J; Lum J; van der Neut Kolfschoten M; Claassens JW; Visser R; Bentlage A; D'Haens GRAM; Verbeek JS; Vidarsson G; van den Brink GR
    Gastroenterology; 2017 Nov; 153(5):1351-1362.e4. PubMed ID: 28756234
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Validation of a Drug-Resistant Anti-Adalimumab Antibody Assay to Monitor Immunogenicity in the Presence of High Concentrations of Adalimumab.
    Bian S; Ferrante M; Gils A
    AAPS J; 2017 Mar; 19(2):468-474. PubMed ID: 27873119
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Restricted immune activation and internalisation of anti-idiotype complexes between drug and antidrug antibodies.
    van Schie KA; Kruithof S; Ooijevaar-de Heer P; Derksen NIL; van de Bovenkamp FS; Saris A; Vidarsson G; Bentlage AEH; Jiskoot W; Romeijn S; Koning RI; Bos E; Stork EM; Koeleman CAM; Wuhrer M; Wolbink G; Rispens T
    Ann Rheum Dis; 2018 Oct; 77(10):1471-1479. PubMed ID: 29945923
    [TBL] [Abstract][Full Text] [Related]  

  • 29. NFκB induces overexpression of bovine FcRn: a novel mechanism that further contributes to the enhanced immune response in genetically modified animals carrying extra copies of FcRn.
    Cervenak J; Doleschall M; Bender B; Mayer B; Schneider Z; Doleschall Z; Zhao Y; Bősze Z; Hammarström L; Oster W; Kacskovics I
    MAbs; 2013; 5(6):860-71. PubMed ID: 24492342
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative Effectiveness and Safety of Anti-Tumor Necrosis Factor Agents in Biologic-Naive Patients With Crohn's Disease.
    Singh S; Heien HC; Sangaralingham LR; Schilz SR; Kappelman MD; Shah ND; Loftus EV
    Clin Gastroenterol Hepatol; 2016 Aug; 14(8):1120-1129.e6. PubMed ID: 27058635
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima.
    Ben-Horin S; Yavzori M; Benhar I; Fudim E; Picard O; Ungar B; Lee S; Kim S; Eliakim R; Chowers Y
    Gut; 2016 Jul; 65(7):1132-8. PubMed ID: 25897019
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Binding characteristics of tumor necrosis factor receptor-Fc fusion proteins vs anti-tumor necrosis factor mAbs.
    Kohno T; Tam LT; Stevens SR; Louie JS
    J Investig Dermatol Symp Proc; 2007 May; 12(1):5-8. PubMed ID: 17502862
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prediction of successful dose reduction or discontinuation of adalimumab, etanercept, or infliximab in rheumatoid arthritis patients using serum drug levels and antidrug antibody measurement.
    Bouman C; van Herwaarden N; van den Hoogen F; van der Maas A; van den Bemt B; den Broeder AA
    Expert Opin Drug Metab Toxicol; 2017 Jun; 13(6):597-604. PubMed ID: 28425772
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adalimumab administration after infliximab therapy is a successful treatment strategy for generalized pustular psoriasis.
    Matsumoto A; Komine M; Karakawa M; Kishimoto M; Ohtsuki M
    J Dermatol; 2017 Feb; 44(2):202-204. PubMed ID: 27743397
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study.
    Bartelds GM; Wijbrandts CA; Nurmohamed MT; Stapel S; Lems WF; Aarden L; Dijkmans BA; Tak PP; Wolbink GJ
    Ann Rheum Dis; 2010 May; 69(5):817-21. PubMed ID: 19581278
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optimizing Treatment with TNF Inhibitors in Inflammatory Bowel Disease by Monitoring Drug Levels and Antidrug Antibodies.
    Steenholdt C; Bendtzen K; Brynskov J; Ainsworth MA
    Inflamm Bowel Dis; 2016 Aug; 22(8):1999-2015. PubMed ID: 27135483
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Generic immune complex assay for detection of murine anti-drug-antibodies in complex with human IgG.
    Boysen L; Sprinkel AME; Lauritzen B; Breinholt J; Lykkesfeldt J; Viuff BM; Landsy LH
    Biologicals; 2019 Jul; 60():42-48. PubMed ID: 31200984
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab.
    Yanai H; Lichtenstein L; Assa A; Mazor Y; Weiss B; Levine A; Ron Y; Kopylov U; Bujanover Y; Rosenbach Y; Ungar B; Eliakim R; Chowers Y; Shamir R; Fraser G; Dotan I; Ben-Horin S
    Clin Gastroenterol Hepatol; 2015 Mar; 13(3):522-530.e2. PubMed ID: 25066837
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Etanercept for patients with psoriasis who did not respond or who lost their response to adalimumab or infliximab.
    Bissonnette R; Maari C; Barber K; Lynde CW; Vender R
    J Eur Acad Dermatol Venereol; 2015 Aug; 29(8):1576-81. PubMed ID: 25600828
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neonatal Fc receptor (FcRn): a novel target for therapeutic antibodies and antibody engineering.
    Wang Y; Tian Z; Thirumalai D; Zhang X
    J Drug Target; 2014 May; 22(4):269-78. PubMed ID: 24404896
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.